HEMATOLOGY-ONCOLOGY
Pharmacologic thromboprophylaxis is usually contraindicated in the following patients Patients with: Active bleeding or intracranial hemorrhage, A surgical procedure is planned in the immediate 6 to 12 hours (eg, spinal neuroaxial anesthesia), A moderate or severe...
HEMATOLOGY-ONCOLOGY
Determines anticoagulation need in hospitalized patients by risk of VTE Risk Factors for VTE in Hospitalized Medical Patients Risk Factor Points Active cancer (Active or treated with chemotherapy and or XRT (X-ray radiation therapy) within the last six months) 3...
HEMATOLOGY-ONCOLOGY
Only anticoagulate hospitalized patients who are at risk for VTE (moderate to high risk). Many hospitalists recommend pharmacologic thromboprophylaxis for patients who have at least one risk factor for VTE and do not have an increased risk of bleeding. Risk Factors...
HEMATOLOGY-ONCOLOGY
Type of Cancer Notes Hypercalcemia squamous cell carcinomas. Up to 80% of cases are due to secretion of parathyroid hormone-related protein Hypercalcemia Breast cancer, lymphomas, and multiple myeloma These may cause hypercalcemia as a result of osteolytic...
HEMATOLOGY-ONCOLOGY
CA-19-9 (Cancer Antigen 19-9) is the most common serum tumor marker used for pancreatic ductal adenocarcinoma, which is expressed in pancreatic and hepatobiliary disease. In symptomatic patients, it can help confirm the diagnosis and aid in assessing the prognosis and...
HEMATOLOGY-ONCOLOGY
See Hypercoagulable State Workup Orders here. The material below is from the following website. Read more here: http://my.clevelandclinic.org/services/heart/disorders/blood-clotting “What causes hypercoagulable states? Hypercoagulable states are usually genetic...
